ALPN - Why Is Alpine Immune Sciences Stock Trading Higher Today? | Benzinga
Alpine Immune Sciences Inc (NASDAQ: ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking session at the American Society of Nephrology (ASN) Kidney Week.
In IgAN, treatment with low-dose povetacicept, 80 mg SC every four weeks, was associated with clinically meaningful improvements in proteinuria, with a 53.5% reduction from baseline in UPCR (n=5) at 24 weeks.
In addition, at 24 weeks, 4/5 (80%) had achieved remission, as defined as UPCR < 0.5 g/g and ≥50% reduction in UPCR from baseline with ...